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ABSTRACT
Objective Cyclosporin-A (CsA) has been reported to
reduce myocardial infarct size in both the experimental
and clinical settings. This protective effect is dependent
on its ability to prevent the opening of the mitochondrial
permeability transition pore, a critical determinant of cell
death in the setting of acute ischaemia-reperfusion
injury. Whether CsA can reduce the extent of peri-
operative myocardial injury (PMI) in patients undergoing
coronary artery bypass graft (CABG) surgery is unknown,
and is investigated in this randomised controlled clinical
trial.
Methods 78 adult patients undergoing elective CABG
surgery were randomised to receive either an intravenous
bolus of CsA (2.5 mg/kg) or placebo administered after
induction of anaesthesia and prior to sternotomy. PMI
was assessed by measuring serum cardiac enzymes,
troponin T (cTnT) and CK-MB at 0, 6, 12, 24, 48 and
72 h after surgery.
Results There was no signiﬁcant difference in mean
peak cTnT levels between control (n=43) and CsA
treatment (n=40) patients (0.56±0.06 ng/mL with
control vs 0.35±0.05 ng/mL with CsA; p=0.07).
However, in higher-risk patients with longer
cardiopulmonary bypass times, there was a signiﬁcant
reduction in PMI with CsA therapy (p=0.049), with a
reduced postoperative cTnT rise by 0.03 ng/mL for every
10 min, when compared with control.
Conclusions In patients with longer cardiopulmonary
bypass times, a single intravenous bolus of CsA
administered prior to CABG surgery reduced the extent
of PMI.
INTRODUCTION
For patients with multi-vessel coronary artery
disease, the treatment of choice is coronary revas-
cularisation by coronary artery bypass graft
(CABG) surgery. In most patients undergoing
routine CABG surgery, the peri-operative risk of
surgery remains low. However, in recent years,
much higher-risk patients are undergoing CABG
surgery. The reasons for this include the ageing
population, the increased prevalence of comorbid-
ities such as diabetes and hypertension, and result
in a higher peri-operative risk, increased risk of
peri-operative myocardial injury (PMI), and worse
clinical outcomes. Crucially, the magnitude of PMI
(as measured by serum cardiac enzymes such as
CK-MB, troponin-T (cTnT) and troponin-I) has
been reported to be associated with worse short
and long term prognosis in patients undergoing
CABG surgery.1–3 This increased risk of PMI
occurs despite current strategies for myocardial
preservation including cross-clamp ﬁbrillation and
blood cardioplegia. As such, novel therapeutic
interventions are required to further protect the
heart during CABG surgery in these high-risk
patients in terms of limiting the extent of PMI and
preserving left ventricular systolic function so as to
improve clinical outcomes.4
In patients undergoing CABG surgery, the heart
is subjected to acute myocardial injury for a
number of different reasons including acute global
ischaemia-reperfusion injury (IRI, as the heart is
put on and taken off cardiopulmonary bypass,
CPB), inﬂammatory injury from CPB, direct
myocardial injury from handling of the heart and
coronary micro-embolisation.4 5 Mitochondrial
dysfunction induced by the opening of the mito-
chondrial permeability transition pore (MPTP) has
been demonstrated to be a critical determinant of
cardiomyocyte death in the heart subjected to acute
IRI.6 7 A number of experimental studies,8–10 and
one recent clinical study,11 have found that admin-
istering cyclosporin-A (CsA) to prevent MPTP
opening at the onset of reperfusion can limit myo-
cardial infarct (MI) size (reviewed in12). Whether,
targeting the MPTP with CsA in adult patients
undergoing elective CABG surgery can reduce the
extent of PMI is not known and is investigated in
the current study.
METHODS
This study received institutional ethical approval
from University College London and King’s
College London. It was registered with the
Multicentre Research Ethical Committee, reference
number 06/Q0502/83 and with the ISRCTN
Register, reference number 49989273. Written
informed consent was obtained from all patients
entering the study.
Between August 2010 and September 2012 con-
secutive adult patients referred for elective CABG
surgery only were recruited. We excluded patients
older than 85 years, with unstable angina, moderate
or severe renal impairment (estimated glomerulo-
ﬁltration rate of less than 45 mL/min/m2), cirrhotic
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liver disease and immuno-compromised conditions. We also
excluded patients taking oral glibenclamide or nicorandil, as
these drugs may interfere with preconditioning.
Computerised-generated random number sequences were used
for randomisation, and blinded treatment allocation was
achieved using opaque numbered envelopes.
After induction of anaesthesia but prior to sternotomy,
patients were randomly allocated to receive either an intraven-
ous bolus of CsA (2.5 mg/kg) in 100 mL NaCl 0.9% over
10 min or an intravenous bolus of 100 mL NaCl 0.9% over
10 min. We used a dose of 2.5 mg/kg, as this was shown to limit
MI size in ST-segment elevation myocardial infarction (STEMI)
patients treated by percutaneous coronary intervention
(PPCI).11 Patients, surgeons, theatre staff, ITU staff and investi-
gators collecting the data were all blinded to the treatment
allocation.
All the following methods were part of the normal induction
and maintenance of general anaesthesia. On arrival in theatre,
all patients received 0.2–0.3 mg/kg midazolam before induction,
and peripheral venous and arterial cannulae were inserted.
Induction of anaesthesia included analgesia with fentanyl, hyp-
nosis with propofol 1–2 mg/kg, and muscle relaxation with atra-
curium 0.5–0.7 mg/kg or rocuronium 0.6 mg/kg. The trachea
was intubated and mechanical ventilation was started thereafter.
The central line was placed in the right internal jugular vein. All
patients received 3 mg/kg of tranexamic acid and 2.5 g of
MgSO4 at the beginning of surgery. General anaesthesia was
maintained with isoﬂurane 1 minimum alveolar concentration
(MAC) and isoﬂurane or propofol infusion during bypass.
Intraoperative analgesics used were remifentanil infusion and
morphine after bypass. Monitoring included continuous arterial
blood pressure, central venous pressure, leads I and V of the
ECG, nasopharyngeal temperature, and trans-oesophageal echo-
cardiography if available.
CPB was started after heparin administration with a non-
pulsatile ﬂow and a membrane oxygenator. Cardioprotection was
provided by cold-blood cardioplegia (1:4), which was adminis-
tered anterogradely, after cross-clamping of the aorta, into the
coronary arteries, or by cross-clamp ﬁbrillation, in both groups.
After grafting, the CPB was discontinued and protamine was
given to reverse the heparin.
Blood samples for measurements of troponin-T and CK-MB
were taken before surgery, and at 6, 12, 24, 48 and 72 h after
surgery. Routine peri-operative blood results included measure-
ments of haemoglobin, white cell count, estimated glomerular
ﬁltration rate, liver transaminases and bilirubin.
Commercially available methods were used to measure
CKMB (IMMULITE 2000, Siemens Healthcare Diagnostics)
and cTnT (Elecsys 1010 System, Roche Diagnostics). The
minimal detectable concentration of CKMB was 0.6 ng/mL and
the reference range was larger than 5 ng/mL. The minimal
detection limit for cTnT was 0.01 ng/mL and the reference
range was larger than 0.1 ng/mL.
Statistical analysis
The primary outcome measure was postoperative peak cTnT
released. For comparison of continuous variables, the t test was
used and for categorical variables the χ2 test. The aim of the
study was to investigate the protective effect of cyclosporine on
myocardial injury as observed with increasing bypass times. The
signiﬁcance of any effect was investigated with model ﬁtting.
Thus, no multiple testing was undertaken as would be the case
for post hoc testing. Multi-level model ﬁtting (MLwiN 2.15)
was used to analyse changes of biochemical markers over time.
Changes in values over time (level 1) in each individual (level 2)
were modelled. An indicator variable was introduced for desig-
nation of the placebo and CsA treatment groups. An interaction
term was introduced to investigate the a priori question of any
effect modiﬁcation in the rise of troponin by CsA from the
length of bypass time. Signiﬁcance was tested using likelihood
ratio testing. Signiﬁcant differences were deﬁned as p<0.05.
Data are presented as mean± SD or SEM. The analysis was
carried out on the basis of intention to treat.
A sample size of at least 72 patients in total was determined
based on the following assumptions from a previous study:13 (a)
a 46% reduction in postoperative peak cTnT level from 0.69 to
0.37 ng/mL with cardioprotective treatment; (b) a SD of
0.48 ng/mL; (c) a power of 80%; and (d) signiﬁcance declared
at the two-sided 5% level.
RESULTS
A total of 224 patients were screened as being eligible for
patient recruitment, of whom 103 agreed to give informed
consent, 80 were randomised and 78 studied with 40 patients in
the CsA and 38 patients in the control groups (see ﬁgure 1).
There were no signiﬁcant differences between the groups in
terms of baseline patient characteristics, intraoperative variables
or routine preoperative blood results (tables 1–3). Serum CsA
levels taken from 10 patients just after the release of the aortic
cross-clamp were found to be within the therapeutic range for
CsA (551±173ng/ml (mean±SD)), conﬁrming that, at the time
of acute global reperfusion, CsAwas present at therapeutic levels.
Table 4 demonstrates a rise in serum CKMB and cTnT post-
operatively in both patient groups indicating the presence of
PMI with surgery. There was no signiﬁcant difference in peak
cTnT at 6 h in CsA treated patients when compared with
control (0.35±0.05 ng/mL with CsA vs 0.56±0.06 ng/mL with
control; p=0.07; table 4). Nevertheless, when the results were
analysed according to the CPB time with multi-level model
ﬁtting, the protective effect of CsA was found to be greater and
the cTnT release during the postoperative time period was lower
in those patients with longer CPB times (p=0.049). The
average cTNT rise was 0.05 ng/mL with every 10 min increase
in the CPB time. However, in those patients who had received
CsA, this increase in cTNTwas less with an average rise of only
0.02 ng/mL of cTnT. Therefore, patients who had received CsA
had an attenuated increase in their average cTnT. Figure 2
demonstrates that the slope of the average cTnT rise is signiﬁ-
cantly less in the group of patients who had been given CsA as
compared with the control group.
The reduced cTnT release in patients with longer CPB times
after a single intravenous bolus of CsA is also illustrated in
ﬁgure 3 where the cTnT rise proﬁle is demonstrated for patients
in our cohort with shorter and longer bypass times. The poten-
tial beneﬁcial effect of CsA in reducing the cTnT rise proﬁle
with increasing bypass times was observed in the group with
longer bypass times of 120 min as compared with those with a
shorter bypass time of 70 min. Thus, the preoperative adminis-
tration of CsA appears to demonstrate a cardioprotective effect
which is more marked the longer the CPB time.
A classical linear mixed model was ﬁtted with random inter-
cept and slopes model was ﬁtted. The main effects of time were
ﬁtted with higher order polynomials of time allowing for a par-
simonious ﬁt. Given the small sample size, we endeavoured to
control for Type I error by ﬁtting random intercepts and slopes
for time. The further randomness introduced with the inclusion
of random slopes to the model reduces type I error.14 Along
with the main effects of time, the main effects of cyclosporine,
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bypass time and their interaction were included to infer any pro-
tective effect of cyclosporine on myocardial injury with longer
exposure to bypass.
Postoperative outcome variables were analysed from prospect-
ively collected data in a subgroup of patients with n=30 in the
control arm and n=32 in the treatment arm. There were no sig-
niﬁcant differences the following outcome measures: length of
hospital stay (7.9±4.2 days with control vs 8.6±3.6 days with
CsA; p=0.53); length of stay in the postoperative critical care
unit (25.7±9.0 h with control vs 27.4±9.8 h with CsA;
p=0.53); and inotrope use (eight patients (27%) in the control
versus eight patients (25%) in the CsA group). The balloon
pump was not needed for inotropic support in any of the
patients postoperatively. Two patients (6%) in the CsA group
and none of the patients in the control group presented with a
postoperative wound infection.
DISCUSSION
In this proof-of-concept clinical study, we investigated for the
ﬁrst time the effects of CsA in adult patients undergoing CABG
surgery. For those patients with longer cardiac bypass times (85–
120 min), we have demonstrated that administering a single
dose of CsA (2.5 mg/kg) prior to CABG surgery reduced the
extent of PMI when compared with control. Importantly, the
administration of CsA as a single intravenous bolus (2.5 mg/kg)
was found to be safe with no related adverse effects, and with
no difference in peri-operative serum markers for renal and
Figure 1 Consort diagram.
Table 2 Patient intraoperative variables
Intraoperative variables CsA (n=40) Control (n=38) p Value
Number of grafts
One 1 (2.5) 1 (3) 0.97
Two 3 (7.5) 5 (13) 0.65
Three 18 (45) 19 (50) 0.83
Four 18 (45) 13 (34) 0.46
Cross-clamp time (min) 54.7 (22.7) 53.9 (23.4) 0.89
Bypass time (min) 92.6 (29.4) 89.2 (28.9) 0.62
Type of cardiac arrest
Cardioplegia 24 (60) 28 (74) 0.48
Cross-clamp fibrillation 16 (40) 10 (26) 0.30
Data are mean (SD) or number (%). CsA, cyclosporin-A.
Table 1 Patient baseline characteristics
Preoperative variables CsA (n=40) Control (n=38) p Value
Age (years) 65.8 (10.7) 67.1 (8.7) 0.20
Gender 0.54
Female 13 (32.5) 9 (24)
Male 27 (67.5) 29 (76)
Diabetes 0.89
None 30 (75) 28 (74)
Non-IDDM 9 (22.5) 8 (21)
IDDM 1 (2.5) 2 (5)
Previous stroke 2 (5) 2 (5) 0.96
Hypertension 29 (72.5) 29 (76) 0.90
Peripheral vascular disease 0 (0) 0 (0)
Hypercholesterolaemia 29 (72.5) 29 (76) 0.90
Previous MI 21 (52.5) 21 (55) 0.99
Smoker 0.26
Never 15 (37.5) 20 (53)
Ex 17 (42.5) 11 (29)
Current 8 (20) 7 (18)
Family history of IHD 19 (47.5) 13 (34) 0.36
BMI 28.8 (4.3) 28.2 (3.5) 0.55
LVEF 0.10
>55% 20 (50) 27 (71)
35%–55% 17 (42.5) 10 (26)
<35% 3 (7.5) 1 (2)
Drug history
Aspirin 34 (85) 34 (89) 0.80
β-Blocker 25 (62.5) 31 (82) 0.11
Cholesterol-lowering drug 31 (77.5) 32 (84) 0.64
ACE inhibitor/AT2RB 27 (67.5) 27 (71) 0.92
Insulin 3 (7.5) 3 (8) 0.95
Metformin 4 (10) 6 (16) 0.67
EuroSCORE 4.8 (2.9) 4.6 (2.7) 0.86
Data are mean (SD) or number (%).
BMI, body mass index; CsA, cyclosporin A; MI, myocardial infarct; IDDM, insulin-
dependant diabetes mellitus; IHD, ischaemic heart disease.
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liver function. It is probably not surprising that the patients
with the longer CPB times beneﬁted most from CsA cardiopro-
tection, as patients with shorter CPB times probably receive
adequate myocardial protection from cross-clamp ﬁbrillation
and cold-blood cardioplegia.
The opening of the MPTP on reperfusion of acutely ischae-
mic myocardium is a critical determinant of cardiomyocyte
death in the setting of acute IRI.6 7 Pharmacological prevention
of its opening at this time using CsA has been reported in a
number of different animal models to reduce MI size in the
region of 30%–40%,8–10 although not all studies have been
positive (reviewed in12). We also applied this therapeutic
approach to ex vivo human heart tissue and demonstrated cardi-
oprotective effects with CsA following simulated IRI in human
atrial trabeculae isolated from right atrial appendage tissue (har-
vested from patients undergoing CABG surgery).15
Piot et al11 were the ﬁrst to apply this therapeutic agent in
the clinical setting, demonstrating that a single intravenous
bolus of CsA (2.5 mg/kg) administered 10 min prior to PPCI
could limit MI size in STEMI patients. Whether CsA can actu-
ally improve clinical outcomes in STEMI patients treated by
PPCI is being investigated in the ongoing 900-patient CIRCUS
study (http://www.clinicaltrials.gov NCT01502774). Although
CsA has been reported to protect against acute IRI in a number
of different experimental settings including stroke, cardiac arrest
and other organ IRI (reviewed in16 17), it has not been investi-
gated as a cardioprotective agent in the setting of CABG
surgery.
In our study, we administered a single dose of CsA prior to
CABG surgery. In patients receiving cold-blood cardioplegia, the
patients would have received a proportion of this dose, recircu-
lating during the administration of cardioplegia. Whether CsA
would have been even more cardioprotective if it had been
added to the cardioplegic solution is not known.
The study limitations include the relatively small size of the
study, and the failure to measure other endpoints of cardiopro-
tection such as LVEF and major adverse cardiovascular events.
However, it is important to appreciate that this study was not
designed or adequately powered to detect the effect of CsA on
these other endpoints. It is also important to bear in mind that
not all patients will be eligible to receive CsA therapy for cardio-
protection given pre-existing medical conditions such as signiﬁ-
cant renal impairment. In this clinical study, the different
methods of myocardial management reﬂect the different prac-
tices by individual surgeons rather than between the two differ-
ent hospitals. A larger study with functional endpoints is needed
to conﬁrm our ﬁndings.
Crucially, in those patients who received the CsA therapy, the
magnitude of PMI (as measured by the serum cardiac enzymes)
was decreased when compared with control, indicating that this
therapeutic approach has protected the myocardium from the
detrimental effects of acute IRI. The magnitude of PMI has
Table 3 Patient peri-operative blood results
CsA (n=40) Control (n=38) p Value
Haemoglobin (g/dL)
Preoperative 12.9 (2.3) 13.6 (2.0) 0.17
Postoperative day 3 9.2 (1.1) 9.7 (1.3) 0.09
White cell count (×109/L)
Preoperative 8.4 (2.3) 7.8 (1.9) 0.22
Postoperative day 3 10.0 (2.8) 9.2 (3.1) 0.24
Urea (mmol/L)
Preoperative 5.9 (1.5) 6.4 (1.8) 0.27
Postoperative day 1 6.2 (1.7) 6.4 (2.1) 0.51
Postoperative day 2 6.7 (2.7) 7.1 (3.2) 0.58
Postoperative day 3 7.0 (3.7) 7.0 (3.1) 0.99
Creatine (mmol/L)
Preoperative 86.9 (16.5) 84.8 (21.7) 0.66
Postoperative day 1 85.5 (21.2) 83.4 (18.9) 0.67
Postoperative day 2 87.1 (33.6) 85.7 (23.3) 0.83
Postoperative day 3 82.5 (27.5) 87.5 (31.3) 0.42
Bilirubin (mmol/L)
Preoperative 9.7 (7.4) 9.6 (5.4) 0.94
Postoperative day 3 11.3 (5.6) 10.1 (3.9) 0.31
ALP (IU/L)
Preoperative 76.3 (32.1) 74.6 (29.6) 0.82
Postoperative day 3 67.1 (29.0) 58.7 (27.3) 0.22
AST (IU/L)
Preoperative 27.7 (8.2) 27.8 (11.7) 0.98
Postoperative day 3 27.4 (10.1) 24.2 (9.0) 0.18
Data are mean (SD) or number (%).
ALP, alkaline phosphatase; AST, aspartate transaminase; CsA, cyclosporin-A.
Table 4 Patient peri-operative serum CK-MB and troponin-T
(cTnT) levels
CsA (n=40) Control (n=38) p Value
CK-MB (ng/mL)
Preoperative 2.2 (0.3) 2.3 (1.5) 0.79
6 h postoperative 21.1 (2.2) 26.5 (16.3) 0.15
12 h postoperative 19.2 (2.3) 22.9 (14.3) 0.30
24 h postoperative 18.9 (2.8) 18.2 (11.9) 0.86
48 h postoperative 8.6 (1.0) 7.3 (4.2) 0.33
72 h postoperative 5.3 (0.6) 4.0 (3.9) 0.20
TnT (ng/mL)
Preoperative 0 0
6 h postoperative 0.35 (0.05) 0.56 (0.06) 0.07
12 h postoperative 0.33 (0.04) 0.44 (0.05) 0.07
24 h postoperative 0.31 (0.03) 0.33 (0.04) 0.87
48 h postoperative 0.17 (0.04) 0.21 (0.03) 0.11
72 h postoperative 0.12 (0.04) 0.12 (0.02) 0.97
Data are mean (SEM).
Figure 2 Effect of CsA on the slope of the average cTnT rise analysed
by multi-level model ﬁtting. For every 10 min increase in the
cardiopulmonary bypass time, patients who had received CsA had an
attenuated increase in their average cTnT rise by 0.03 ng/mL. CsA;
cyclosporin-A.
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been linked to worse clinical outcomes post-CABG surgery;
whether CsA therapy is able to impact on prognosis in this
patient group is unknown and needs to be determined in a suit-
ably powered clinical study.
The data from this and the clinical study by Piot et al11 impli-
cate MPTP inhibition as a viable therapeutic strategy for cardio-
protection, but it must be appreciated that CsA is a non-speciﬁc
MPTP inhibitor with potential side-effects. These include
immunosuppression (resulting in increased risk of wound
infection), renal dysfunction and hypertension in the peri-
operative period, although the risk of these side-effects was
limited due to only a single dose of CsA being administered.
However, in order for this therapeutic approach to be imple-
mented in the clinical setting, more potent and speciﬁc MPTP
inhibitors will need to be discovered.
We conclude that the administration of a single dose of CsA
prior to CABG surgery can reduce PMI in higher-risk patients
with longer CPB times. Large multi-centre clinical studies will
be required to conﬁrm these results and to investigate whether
MPTP inhibition can improve clinical outcomes in patients
undergoing CABG surgery.
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